OTCMKTS:RZLTD

Rezolute Stock Forecast, Price & News

$6.36

-0.53 (-7.69 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.36

Now: $6.36▼

$7.49

50-Day Range

$6.83

MA: $10.69▼

$20.52

52-Week Range

$16.00

Now: $6.36▼

$24.05

Volume15,913 shs

Average Volume4,788 shs

Market Capitalization$53.54 million

P/E RatioN/A

Dividend YieldN/A

Beta4.37

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:RZLTD

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.rezolutebio.com

Phone650 206 4507

Employees23

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio3.26

Quick Ratio3.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.24 per share

Price / Book5.13

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-20,330,000.00

Net MarginsN/A

Return on Equity-153.46%

Return on Assets-111.71%

Miscellaneous

Outstanding Shares8,418,000

Market Cap$53.54 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
January 12, 2021 | finance.yahoo.com

What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)?
January 11, 2021 | finance.yahoo.com

FDA Clears Rezolute’s IND Application for RZ402
December 3, 2020 | finance.yahoo.com

Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 19, 2020 | finance.yahoo.com

RZLTD Real-Time Quotes
November 15, 2020 | nasdaq.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1846th out of 2,016 stocks

Pharmaceutical Preparations Industry

736th out of 771 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Rezolute.

0.0 Community Rank

Outperform Votes
Rezolute has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rezolute has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Rezolute and other stocks. Vote “Outperform” if you believe RZLTD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RZLTD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rezolute does not currently pay a dividend.
Dividend Growth
Rezolute does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rezolute insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Rezolute is held by insiders.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Rezolute has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$6.36

-0.53 (-7.69 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RZLTD News and Ratings via Email

Sign-up to receive the latest news and ratings for RZLTD and its competitors with MarketBeat's FREE daily newsletter.

Rezolute (OTCMKTS:RZLTD) Frequently Asked Questions

What stocks does MarketBeat like better than Rezolute?

Wall Street analysts have given Rezolute a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rezolute wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Rezolute's key executives?

Rezolute's management team includes the following people:

Mr. Nevan Charles Elam, CEO & Director (Age 53, Pay $869.45k)
Dr. Keith A. Vendola M.B.A., M.D., MBA, Chief Financial Officer (Age 48, Pay $422.76k)
Dr. Sankaram Mantripragada, Chief Scientific Officer (Age 60, Pay $620.76k)
Mr. Michael R. Deperro, Head of Operations
Dr. Brian Roberts, Head of Clinical Devel.
Ms. Paula Opal, Head of Regulatory
Dr. Sharon Xueyan Wang, Head of Preclinical Devel.

Who are some of Rezolute's key competitors?

Some companies that are related to Rezolute include Lannett (LCI), PLx Pharma (PLXP), Medicenna Therapeutics (MDNA), NuCana (NCNA), Novan (NOVN), vTv Therapeutics (VTVT), Kindred Biosciences (KIN), Matinas BioPharma (MTNB), Tiziana Life Sciences (TLSA), Jaguar Health (JAGX), Tyme Technologies (TYME), Oasmia Pharmaceutical AB (publ) (OASMY), Sierra Oncology (SRRA), Galera Therapeutics (GRTX) and Osmotica Pharmaceuticals (OSMT).
View all of RZLTD's competitors.

What is Rezolute's stock symbol?

Rezolute trades on the OTCMKTS under the ticker symbol "RZLTD."

How do I buy shares of Rezolute?

Shares of RZLTD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rezolute's stock price today?

One share of RZLTD stock can currently be purchased for approximately $6.36.

How much money does Rezolute make?

Rezolute has a market capitalization of $53.54 million.

How many employees does Rezolute have?

Rezolute employs 23 workers across the globe.

What is Rezolute's official website?

The official website for Rezolute is www.rezolutebio.com.

Where are Rezolute's headquarters?

Rezolute is headquartered at 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065.

How can I contact Rezolute?

Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The company can be reached via phone at 650 206 4507 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Rezolute Stock Forecast, Price & News

Adding

Adding

Adding Rezolute, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes

0.0 Dividend Strength

Dividend Yield

Dividend Growth